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Abstract
Background: G Protein-Coupled Receptors (GPCRs) are a large and diverse family of membrane 
proteins whose members participate in the regulation of most cellular and physiological processes 
and therefore represent key pharmacological targets. Although several bioinformatics resources 
support research on GPCRs, most of these have been designed based on the traditional assumption 
that monomeric GPCRs constitute the functional receptor unit. The increase in the frequency and 
number of reports about GPCR dimerization/oligomerization and the implication of 
oligomerization in receptor function makes necessary the ability to store and access information 
about GPCR dimers/oligomers electronically.
Results: W e  present here the requirements and ontology (the information scheme to describe 
oligomers and associated concepts and their relationships) for an information system that can 
manage the elements of information needed to describe comprehensively the phenomena of both 
homo- and hetero-oligomerization of GPCRs. The comprehensive information management
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scheme that we plan to use for the development of an intuitive and user-friendly GPCR- 
Oligomerization Knowledge Base (GPCR-OKB) is the result of a community dialog involving 
experimental and computational colleagues working on GPCRs.
Conclusion: Our long term goal is to disseminate to the scientific community organized, curated, 
and detailed information about GPCR dimerization/oligomerization and its related structural 
context. This information will be reported as close to the data as possible so the user can make his 
own judgment on the conclusions drawn for a particular study. The requirements and ontology 
described here will facilitate the development of future information systems for GPCR oligomers 
that contain both computational and experimental information about GPCR oligomerization. This 
information is freely accessible at http://www.gpcr-okb.org.
Background
G Protein-Coupled Receptors (GPCRs) are among the 
largest and most diverse protein families in mammalian 
genomes, and constitute the largest single family of thera­
peutic targets for drug treatment. They are integral mem­
brane proteins with a central common core made of seven 
transmembrane helices connected by intracellular and 
extracellular loops (Figure 1). The primary function of 
GPCRs is to transduce extracellular stimuli into intracellu­
lar signals through G-protein dependent and independent 
pathways.
The traditional view of GPCR function had focused on the 
assumption that monomeric receptors participated in lig­
and binding and signal transduction processes (Figure 
1a). Specifically, a single ligand was assumed to activate a 
single receptor by producing a conformational change in 
the receptor that would induce activation of a G protein or 
effector. Although it is well accepted that a monomeric 
GPCR can activate heterotrimeric G-proteins, the view 
that they function only as monomers in cells has recently 
been challenged by the discovery that numerous GPCRs
F ig u re !
Traditional and current views of G P C R  signaling. The
traditional view of GPCR signaling assumed that monomeric 
receptors participated in ligand binding and signal transduc­
tion. The current view suggests that GPCRs may form homo- 
and/or hetero-oligomers, and that ligand(s) binding to one or 
more receptors may activate neighboring receptors in the 
oligomeric complex.
form homo- and/or hetero-oligomers (Figure 1b). Func­
tional crosstalk between protomers in a dimeric or oligo­
meric complex has been described, and it is possible that 
ligand binding to one or more receptors may activate 
neighboring receptors in an oligomeric complex, giving 
rise to a cascade of interconnected signaling events.
The physiological relevance of GPCR oligomerization is 
largely accepted nowadays, especially in light of the dis­
covered functional implications of GPCR association that 
include pharmacological diversity, G-protein coupling 
specificity, downstream signaling amplification or attenu­
ation, and/or internalization (see [1-9] for recent 
reviews). This growing amount of information and its 
required incorporation into physiologically relevant func­
tional models of GPCRs encourages the development of a 
publicly accessible repository of information focused on 
GPCR homo- and hetero-oligomers.
Currently available bioinformatics tools for data storage 
devoted to GPCRs have been designed with a strong 
emphasis on receptor monomers. For example, informa­
tion repositories such as GPCRDB [10] and tGRAP [11] 
include sequence data, alignments of monomers, 2D vis­
ualization of m onom er units, and m utation information 
for receptor mutants. The NC-IUPHAR (The International 
Pharmacology Committee on Receptor Nomenclature 
and Classification) database on GPCR nomenclature and 
drug classification [12] includes the most commonly 
studied GPCRs with a particular focus on information 
about their pharmacological and functional properties, 
and their function, and localization in vivo. These infor­
m ation systems have proven extremely useful to support 
structural and functional studies of GPCRs, as shown by 
their strong user base. For instance, GPCRDB has estab­
lished itself as a central repository for GPCR information 
with peak access at some 100,000 requests per month 
[10]. Information systems such as GPCRDB provide users 
with a unified view of information in a given field (or for 
a class of molecules), and constitute frequently updated 
resources that support structured queries and provide 
advanced visualizations.
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Given that physiologically relevant functional models of 
GPCRs must incorporate GPCR homo- and/or hetero-oli- 
gomeric constructs, the explosion of information about 
GPCR oligomerization makes this an opportune time for 
the development of a web-based information system that 
specifically a) stores computational and experimental 
information about GPCR oligomerization, and b) allows 
browsing, visualization and structured querying of its con­
tents. Such a system would foster and support productive 
and quantitative communication and collaboration 
between computational and experimental scientists, but is 
not currently available in any form. To best serve the 
broad GPCR community by providing a comprehensive 
and reliable (data-driven, rather than interpretation- 
driven) GPCR oligomerization information system, it is 
im portant that opinions from GPCR experts in both 
experimental and computational fields are given due con­
sideration. This manuscript describes the result of a com­
munity dialog we initiated to identify the requirements 
for a comprehensive GPCR oligomerization information 
system and to design an ontology (information scheme) 
to represent such information. The GPCR oligomerization 
ontology that we present here is a formal description of 
the information concepts required to describe GPCR oli­
gomerization and of the relationships between these con­
cepts. As such, this ontology allows the organization of 
information in a formal way, a prerequisite to supporting 
many of the requirements that potential users identified 
for the future GPCR oligomerization information system 
(see Information System Requirements below).
Results
An information system devoted to homo- and hetero-oli­
gomers of GPCRs requires the capability to store, and 
allow browsing, visualization and structured querying of 
a specialized set of heterogeneous data. To facilitate the 
implementation of a comprehensive information system 
focused on GPCR oligomerization, it is im portant to 
make informed decisions about the specific usages the 
information system will support and what type of infor­
mation must be stored and queried. Thus, in a first step 
towards developing such a system, we have obtained sys­
tem requirements -  a list of features essential to the fin­
ished information system -  from experts in the GPCR 
oligomerization field, and have developed an ontology to 
represent the results of GPCR oligomerization studies 
(both experimental and computational). The system 
requirements and ontology constitute a comprehensive 
information management scheme for a GPCR oligomeri­
zation information system and can be used to guide the 
fine design and implementation of such a system. 
Throughout the ontology and this manuscript we define 
the word 'protomer' to refer to a protein which is a constit­
uent part of an oligomer. In contrast, we reserve the word 
'monomer' for stand-alone GPCR proteins.
Information system requirements
In the following sections, we report the system require­
ments that have been identified for a comprehensive 
GPCR oligomerization information system. Each require­
m ent describes a high-level feature that an information 
system for GPCR oligomers must include to be useful, and 
explains how this feature will support studies of GPCR oli­
gomers.
1. Providing an electronic repository of both experimental and 
computational information about GPCR oligomers
The repository will complement the scientific literature by 
offering a unified view of the data and/or conclusions 
published in different articles. One of the most daunting 
obstacles encountered when directly searching the litera­
ture is the existence of varying monomer/oligomer nam ­
ing schemes or different residue numbering conventions. 
This makes it extremely difficult to locate articles of inter­
est using current text searching methods. A useful GPCR 
oligomerization information system should make it pos­
sible to bypass this problem by supporting the creation of 
unified views by aggregating data along different axes. In 
an information system for GPCR oligomers, aggregation 
could be done at the level of the oligomer or structural 
domain, so that obtaining the list of small molecules that 
were shown to bind an oligomer would be possible even 
if the information was originally published in five articles 
where the same oligomer was referred to by three different 
names. The GPCR oligomerization information system 
should therefore eliminate the common problems 
encountered when searching the literature with current 
text searching methods. A GPCR information system 
should also provide links to the primary literature for each 
fact or interpretation offered.
Native oligomeric complexes of GPCRs that satisfy any or 
all of the rules recently stipulated by NC-IUPHAR [13] 
should and will be properly highlighted.
2. Linking and complementing existing GPCR resources that provide 
information about GPCR monomers
There is a rich compendium of established and experi­
mental bioinformatics resources designed to support 
GPCR research (e.g., GPCRDB [14], tGRAP [11], 
GPCRIPDB [15], NC-IUPHAR [12], Arcadia [16]). A 
GPCR oligomerization information system should not 
duplicate existing m onom er resources, bu t rather should 
focus on interfacing with these resources to im port data or 
to link to them to relate oligomer-specific data to known 
facts about their constituent protomers. This information 
is needed to reveal possible changes in the structure-func- 
tion relations of a specific GPCR oligomer compared to its 
monomeric forms. Information available about the m on­
omers found in existing resources includes but is no t lim­
ited to: transmembrane (TM) helical boundaries,
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sequence alignments, phylogenetic trees, predictions of 
solvent accessibility of TM residues, snake-like diagrams, 
three-dimensional (3D) molecular models, Protein Data 
Bank (PDB) files associated with GPCRs, point mutations, 
GPCR interacting partners, GPCR cDNAs, chromosomal 
locations, and ligand-binding constants. Similarly, a 
GPCR oligomerization information system should pro­
vide the capability for others to define links to data entries 
in the information system. For instance, in the systems to 
which GPCRDB links, this requirement is fulfilled when 
linked resources export a catalog of the internal and exter­
nal accession codes for each data item that they contain. 
Developments at GPCRDB, such as the creation of web 
services, will facilitate this integration with GPCR-OKB.
3. Providing information about the experimental details of the 
method used in published studies of GPCR oligomers
A variety of experimental procedures and systems has 
been used to study GPCR oligomers. A comprehensive 
information system involving GPCR oligomers should 
include information about: i) the experimental procedure 
used to characterize the oligomer, e.g., Fluorescence Reso­
nance Energy Transfer (FRET), Bioluminescence Reso­
nance Energy Transfer (BRET), Time Resolved FRET (TR- 
FRET), cross-linking, co-immunoprecipitation, co-expres­
sion of fragments or modified protomers, Atomic Force 
Microscopy (AFM), or use of dimer-specific antibodies 
(for a complete review see [17]); ii) the biological system 
studied, e.g., native tissue/transfected cells; and iii) the 
evidence available for cross-modulation of ligand bind­
ing, activation, internalization, e.g., see [18,19]. The user 
should be able to search for single or multiple experimen­
tal details, in order to identify the multimeric complexes 
that have been studied under specified conditions. Knowl­
edge of experimental details used in published studies of 
GPCR oligomers will allow users to have a better under­
standing of the corresponding results. In addition, it will 
assist the user in the design of directed pharmacological 
and physiological experiments for the specific multimeric 
system under study.
4. Providing experimental and computational results rather than 
interpretation of those data
Scientific publications contain descriptions of experimen­
tal results and of the methods used to produce them. In 
contrast, it is not unusual for the interpretation of the data 
presented in a manuscript to be challenged in follow-up 
publications, as more experimental data become availa­
ble. Because various interpretations of the data are often 
the object of debate until a consensus is reached, the 
information system will be most helpful if it stores the 
experimental data. In the case of conflicting data, all 
experimental results will be reported, with the appropriate 
reference.
5. Providing information about the specific residues at oligomeric 
interfaces established or predicted by experimental and/or 
computational approaches
A detailed information system about GPCR oligomers 
should include information about the experimental 
m ethod (e.g., cross-linking [1] or site-directed mutagene­
sis) or computational procedure (e.g., evolutionary trace 
(ET) method, correlated m utation analysis (CMA), sub­
tractive correlated m utation (SCM), etc.) used to deter­
mine/predict dimerization/oligomerization interfaces 
[20]. Availability of information about the composition 
of the interfaces of dimerization/oligomerization will 
facilitate an understanding of the nature of the interaction 
between GPCR subunits. This information is essential to 
the design of oligomerization-disrupting mutants directed 
towards modulating GPCR function. Interface residues 
should be identified both by the absolute sequence num ­
bering and by a GPCR generic numbering system, which 
makes it possible to refer, comparatively, to structurally 
cognate GPCRs. For family A GPCRs, this generic number­
ing system consists of assigning each helix residue a 
num ber relative to that of the most conserved residue in 
each transmembrane helix, which is arbitrarily assigned 
the num ber 50 [21]. Different sets of index residues are 
selected for other GPCR families, i.e., family C GPCRs
[22]. As generic numbering systems for other families are 
proposed, they will be incorporated.
6. Providing structural information about physiological GPCR 
oligomers
Information about the particular experimental method 
used to obtain the structural information (e.g., X-ray dif­
fraction in the case of the extracellular domain of mem­
bers of family C GPCRs) and/or the specific type of 
modeling procedure (e.g., distance-based modeling in the 
case of rhodopsin) should be stored and detailed as com­
pletely as possible. Results from several computational 
techniques, including molecular dynamics simulations
[23], should also be considered for storage as they are 
expected to help rationalize possible dynamic mecha­
nisms of GPCR oligomers and suggest potential ways of 
modifying receptor function.
7. Providing information about potential mechanisms of activation of 
GPCR oligomers
The user should receive detailed information when avail­
able about i) activated protomer(s) within the oligomer; 
ii) the activating ligands; iii) single or multiple occupancy 
of binding sites; iv) types of conformational change 
within each protomer; v) symmetric/asymmetric func­
tioning; vi) cis- or trans-activation; vii) possible structural 
rearrangement at the interface upon activation; viii) 
GPCR-G-protein stoichiometry. Although most of this 
information derives from paradigms of G protein- 
dependent signaling, inferences from G-protein inde­
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pendent pathways will also be incorporated as more 
detailed information becomes available.
8. Providing detailed information about functional roles of GPCR 
oligomers
The user will find beneficial the following information: i) 
role of oligomerization in maturation and cell-surface 
delivery; ii) ligand regulation (and characterization of the 
ligand as agonist or antagonist); iii) cross-modulation of 
signaling/binding; iv) negative/positive cooperativity; v) 
attenuation/potentiation of signaling in G protein- 
dependent and independent pathways; vi) G-protein spe­
cificity; vii) internalization (for a recent review see [2]). By 
searching for single or multiple functional details, the user 
should easily identify the multimeric complexes that sat­
isfy such criteria.
9. Linking to novel compounds that are proposed to selectively target 
GPCR oligomers
Recent evidence for compounds that can selectively acti­
vate hetero-oligomers bu t not homo-oligomers suggests 
that GPCR hetero-oligomers can be used as models in the 
development of new therapies [24], as well as in the 
design of new drugs with reduced side effects [8,25,26]. 
Therefore, the user will find helpful a connection between 
the detailed information available for these multimeric 
systems and the compounds they are purported to recog­
nize and bind. To this end, the information system should 
link to databases (e.g., PubChem [27]) that contain infor­
mation about the chemical and structural features of both 
synthetic and natural compounds, as well as their vendor 
identifier if available. Antibodies that selectively target 
GPCR oligomers will also be included in the information 
system.
10. Providing information about the physiological relevance of GPCR 
oligomers
One of the m ain requirements for the recognition and 
acceptance of GPCRs multimeric receptors recently 
defined by NC-IUPHAR [13] is a firm demonstration of 
the actual physiological relevance of those oligomeric 
complexes/receptors. This is especially im portant in the 
case of hetero-oligomers, for which most of the results 
come from heterologous cellular systems where two dif­
ferent GPCRs are co-expressed simultaneously. Therefore, 
information concerning co-localization studies in native 
tissues, in vivo effects of hetero-oligomer specific ligands 
as well as reported in vivo phenotypical changes (e.g., 
pharmacological response or cooperativity) in knock-out 
animals should be available to the user.
A comprehensive ontology for the study o f GPCR 
oligomers
The requirements presented in the previous section call 
for the management of various types of information
about the oligomers, their structural domains, or their 
binding ligands. Because each of these information types 
relates to one or more other information types, and 
because the relationship between such types can become 
complex, it is necessary to specify precisely the informa­
tion type relationships that the information system will 
support. To achieve this, we have created a formal ontol­
ogy for a comprehensive GPCR oligomerization informa­
tion system currently under development in our 
laboratories. The term ontology is commonly used in bio­
informatics to denote various types of ways to organize 
biological information (from the directed acyclic graph of 
the "Gene Ontology" to frame-based systems). Here, we 
consider that an ontology is the result of making choices 
to represent a specific aspect of reality, e.g., a biological 
entity such as a GPCR oligomer within an information 
system, database, or knowledge representation system, in 
order to make it amenable to certain types of computa­
tions (we therefore follow the definition of an ontology 
given in [28]). Choices are necessary to simplify the repre­
sentation so that it only maintains the attributes needed 
for the type of computational use planned. From the use 
case scenarios and system requirements obtained as a 
result of an interdisciplinary effort, we have incorporated 
the elements of information that are required to describe 
sufficiently the phenomena of GPCR homo- and hetero­
oligomerization, and also how these elements of informa­
tion combine to form a system that will serve the targeted 
users. The ontology is a crucial com ponent of the informa­
tion management scheme for an information system 
because it formally specifies what can be stored in such a 
system and what types of computations can be performed 
with the stored material. The rest of this section describes 
in detail the ontology developed for a comprehensive 
GPCR oligomerization information system. The full 
ontology is depicted in Figures 2, 3, and 4, and is available 
in OWL format from the project web site [29]. A specific 
example is illustrated in Figure 5.
1. Ontology primer
1.1 The Oligomer concept
The Oligomer concept is central to the GPCR-OKB, and 
we use it here to define the conventions followed in the 
rest of this manuscript. Figure 2 shows the Oligomer con­
cept with its connections to other concepts of the ontol­
ogy. In this manuscript, all graphical representations of 
the ontology follow the UML conventions [30]. Briefly, 
concepts are depicted by rectangular boxes with their cor­
responding names reported in the top portion of the box. 
Open-ended arrows from one concept to another indicate 
that the destination concept is more general than the 
source concept (those arrows can be read: 'source "is a" 
destination'). Other arrows indicate relationships 
between concepts. Attributes of a concept are reported 
within each concept box. Attributes conventionally begin
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Figure2
U M L  diagram of the O ligom er concept and related concepts. Each concept is shown as a box, and is named in the top
section of the box. All attributes for each concept are listed in the middle section of the box. Arrows represent relationships 
between concepts, and open-ended arrows indicate "is a" relationships. The relationship of one concept to another is indicated 
by the text on each arrow. Arrows with [0..*] (zero or more) or [1..*] (one or more) indicate the number of instances of the 
concept at the end of the arrow that is associated with the concept at the beginning of the arrow. The Oligomer concept is 
central to the GPCR oligomerization ontology and all other concepts in the ontology relate to it either directly (e.g., Oligomer 
''is described by'' IdentificationStudy) or indirectly (e.g., Oligomer ''is composed of" one or more [1..*] Protein that ''belongs 
to'' Family).
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Figure3
U M L  diagram of modeling-related concepts. Structural models of Oligomers are represented in the GPCR oligomeriza­
tion ontology by a MolecularStructure concept. Each MolecularStructure is created with an instance of MethodType, and may 
be analyzed by many computational methods (instances of Analysis). MethodType has two subclasses: IdentificationMethod, 
which is used to identify the oligomer, and CreationMethod, which is used to create the MolecularStructure. Identification­
Method and CreationMethod can have many sub-concepts that describe the precise type of method. In this figure we show 
only a few examples of such concepts.
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Figure4
U M L  diagram of concepts related to oligomerization-induced phenotype changes. The GPCR oligomerization 
ontology focuses on changes in the phenotype that occur when GPCR protomers oligomerize. There are three types of phe­
notypic change that are described by the ontology: changes in internalization, changes in signaling, and differences in the ligand 
binding of the oligomer as compared to any of the constituent protomers. The effect that ligand(s) binding to one or more of 
the protomers in an oligomer may have on binding of ligands to other protomers, or on the change in signaling, is described by 
the CrossTalk concept. The Internalization concept is used to describe changes that different ligands have on the trafficking of 
the Oligomer to the cell membrane. Any information that is available about the mechanism of activation of the Oligomer is 
stored in the MechanismOfActivation concept. The PhysiologicalRelevance concept stores information about the Oligomer in 
vivo.
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Figure5
U M L  diagram of the oligomerization-induced cooperativity effects in HEK-293 cells co-expressing ^-opioid and 
S-opioid receptors. The attribute bindingXTalk compiles any information related to changes in the affinity of the ligandUnderT- 
est (DAM GO) in the presence of another ligand (e.g., TIPP T , deltorphin II, SNC80, or DPDPE). Treatment of HEK-293 cells 
with the selective S-opioid ligand TIPP T  results in increased binding of the ^-opioid agonist DAMGO (see CrossTalkl). 
Among the S-opioid selective agonists SNC 80, DPDPE or deltorphin II, only the last leads to a significant increase in 
DAMGO's binding affinity (see CrossTalk2-4).
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with lowercase letters. If the attribute name is made up of 
two or more words, the subsequent words are capitalized 
to make it easier to understand the name of the attribute. 
For example, Figure 2 shows that the Oligomer concept 
has an attribute oligomerName of type String that stores the 
name of the Oligomer. The Oligomer concept also has a 
protomers attribute that lists the specific protein types that 
form the oligomer. The ontology does no t track the exact 
stoichiometric subunit composition of oligomers because 
most of the time this information is not known. Instead 
the ontology records what types of GPCRs are known or 
predicted to participate in that instance of Oligomer. For 
instance, to indicate that the 8-opioid receptor is predicted 
to oligomerize with the ^-opioid receptor, an instance of 
the Oligomer concept is created with a protomers attribute 
that references these two GPCRs. The protomers attribute is 
of type Collection<Protein>, a notation that indicates that 
this attribute can contain a number of instances of the 
Protein concept. The num ber of Protein instances that can 
participate in the relation defined by the protomers 
attribute is specified on the arrow from Oligomer to Pro­
tein. This is an example of an association between one 
concept and another, where one concept can have multi­
ple instances of the other concept. In a UML diagram, 
such multiplicities of association are indicated at the start 
of the arrow between the two concepts. In this case, the 
notation 1..* indicates that an instance of Oligomer may 
have one or more Protein instances in its attribute protom­
ers, where the 1 indicates that an Oligomer must have at 
least one Protein associated with it, and the * indicates 
that there can be more than one Proteins associated with 
the Oligomer. Similarly, it is possible (for example in the 
association from Protein to Oligomer), that a Protein may 
not be a part of any Oligomer at all, or may be a compo­
nent of many different Oligomers. In this case, the nota­
tion reads 0..* (see Figure 2).
1.2 ExternalReference
Similarly to the protomers attribute, the literatureReferences 
attribute indicates that each instance of the Oligomer con­
cept is associated with one or more (1..*) ExternalRefer­
ence instances. The literatureReferences attribute allows 
citations and other outside references to be attached to a 
particular Oligomer instance. The ExternalReference con­
cept performs this function because its three attributes 
(externalID, resourceType and otherReferenceInfo) allow the 
identification of published material and external database 
links associated with that Oligomer instance. For exam­
ple, an ExternalReference instance whose attributes are 
{externalID = 10926528, resourceType = PubMed and oth­
erReferenceInfo = refers to an article in PubMed whose 
primary identifier is 10926528. This information is suffi­
cient to identify the article describing the crystal structure 
of rhodopsin [31]. Articles that are not indexed in 
PubMed can also be referenced. A reference to this same
article can also be constructed by using a DOI resource 
type: {externalID = 10.1126/science.289.5480.739, 
resourceType = DOI and otherReferenceInfo = ""} [32]. The 
ExternalReference concept thus allows the cross-linking to 
any piece of information that is available online and is in 
the public domain. Other types of references that are not 
accessible through the above mechanism can be cited 
using the otherReferenceInfo attribute.
1.3 TrackedEntity
The TrackedEntity concept shown in Figure 2 provides an 
internal identifier that allows other systems to link to data 
entries in the information system. Each concept of the 
GPCR-OKB ontology that other systems could find useful 
to link to (e.g., Oligomer, Protein, Family, Ligand and 
IdentificationStudy in Figure 2) inherits the identifier 
attribute by extending the TrackedEntity concept. In Fig­
ure 2, this is shown graphically either with the open- 
ended arrow "is a" relation, or by the <<TrackedEntity>> 
special tag. The TrackedEntity concept can be extended 
with attributes to track accession codes over time and revi­
sion information.
2. Molecules
In Figure 2, the concepts Oligomer, Ligand and Protein 
represent molecules. The Oligomer concept is defined by 
the following attributes: oligomerName, protomers, studies, 
literatureReferences, rules, mechanismsOfActivation, isFor- 
medInER, physiologicalRelevance, and structuralModels. The 
attributes oligomerName, protomers, and literatureReferences 
have already been described in the previous section. Other 
attributes of the Oligomer concept are described below.
2 .1 Oligomer
The attribute rules stores information on whether the Oli­
gomer conforms to the list of recommendations recently 
stipulated by the NC-IUPHAR subcommittee for the rec­
ognition and nomenclature of GPCR multimers 
(described in [13]). The concept NciupharRules, also 
shown in Figure 2, indicates which of the NC-IUPHAR 
rules the given Oligomer satisfies. These rules, which 
ensure the existence of an oligomer, are: 1) evidence of 
physical association; 2) identification of a specific oligo­
meric function; and 3) evidence for the existence of the 
oligomer in vivo. Each of the three rules has an attribute 
associated with it. Each attribute is of a boolean type, 
meaning that it can either be TRUE or FALSE.
Oligomers may be assembled either in the endoplasmic 
reticulum (ER) and then exported to the cell membrane, 
or the individual protomers that form the oligomer may 
be exported separately to the cell membrane and the oli­
gomer be assembled there. The attribute isFormedInER 
refers to the formation of the oligomer in the ER. A proto­
typical example of an oligomer formed in the ER, and sub­
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sequently exported to the membrane (receptor 
maturation/ontogeny) is the heterodimeric y-aminobu- 
tiric acid GABAb receptor. In fact, subunit GABAB1 is usu­
ally retained in the ER, and only its dimerization with 
subunit GABAB2 allows for the export of the functional 
heterodimer to the plasma cell membrane [33-35]. Simi­
lar behavior has recently been described for some mem­
bers of the class A GPCRs such as aB and aD-adrenergic 
receptors heterodimers [36], vasopressin V1a, V2, and the 
oxytocin receptors homo- and heterodimers [2], C5a 
homodimers [37], and others. Thus, for these oligomers, 
the isFormedInER attribute is TRUE. When new techniques 
become available that allow the unambiguous verifica­
tion of export to the cell membrane, then such data will 
also be included in the information system.
Other attributes of the Oligomer concept, such as studies, 
mechanismsOfActivation and physiologicalRelevance, 
describe more detailed information related to the oli­
gomer; any structural information available for the oli­
gomer is detailed in  the attribute structuralModels. These 
information concepts are depicted in Figures 3 and 4 and 
will be discussed in the following sections.
2.2 Ligand
In Figure 2, the Ligand concept refers to any molecule that 
binds to a receptor (e.g., small molecules or peptides). 
Ligands have a name m eant for display in the user inter­
face (ligandName), and a collection of external references 
(databaseReferences). These references make it possible for 
users to follow links to databases where the small mole­
cule, peptide, or protein ligand is described in detail (e.g., 
PubChem [38]). We can also represent novel compounds 
by their canonical SMILES representation (smilesStruc- 
ture). An introduction to canonical SMILES is provided by 
[39].
2.3 Protein
The Protein concept represents individual protein chains 
or protomeric units, defined by the attribute proteinName. 
The organism attribute stores the Latin names for the 
source organism. A more detailed description of the Pro­
tein is stored in the description attribute. The databaseRefer- 
ences attribute of protein makes it possible to non- 
ambiguously identify the protein in external databases. 
The oligomers attribute lists the Oligomers in which the 
protein participates. The attribute tmTopology defines the 
location of the transmembrane segments (TM) used when 
determining the generic numbering attributes (see 
below), and also supports creating snake-like plots of the 
oligomerization interface where interacting residues are 
highlighted [40]. Each TM is encoded by an instance of 
SecondaryStructureElement (see below). Protein is further 
qualified with the most specific GPCR family to which it 
belongs (see below). Note that we use the term 'family' for
any set of related proteins on a number of different levels 
which include super-families, families and classes of pro­
teins. This simplification makes it possible to re-use the 
same ontology concept (called 'Family') for all levels of 
hierarchy.
2.4 SecondaryStructureElement
This concept stores information about each individual 
secondary structure element in a GPCR protein, such as 
helices. The helical boundaries for family A GPCRs are 
based on the alignment with the rhodopsin crystal struc­
ture. Helical boundaries for all other families of proteins 
will be defined by secondary structure predictions and 
hydropathy profiles. Its attributes include startPosition 
(the absolute position in the protein where the element 
starts), endPosition (the absolute numbering of the end of 
the element) and elementName (the conventional name 
given to the secondary structure element. For example, the 
third transmembrane segment of the bovine ^-opioid 
receptor would be stored as startPosition = 107, endPosition 
= 139 and elementName = TM3.
2.5 Family
The Family concept supports a typical hierarchical organ­
ization of protein families (parent and children attributes). 
For instance, the opioid receptor family has three children 
(= opioid receptor type D, opioid receptor type K, and opi­
oid receptor type M). The opioid receptor type D family 
then has one parent (= opioid) and one child (= 8-opioid 
receptor). The name of the family is stored in familyName, 
and the proteins that comprise the family are stored in 
memberProteins. Any references in online databases to this 
family are stored in databaseReferences.
3. Studies of oligomer and interface identification
3.1 IdentificationStudy
The IdentificationStudy concept describes the studies and 
methods that led to the identification of an oligomer or 
the interacting structural domains of the protomers at the 
oligomeric interface. The methodType attribute describes 
the type of method used in the study and is described in 
more detail in the following section. The phenotype 
attribute indicates if any phenotypic changes were 
observed in the referenced study. (The concept Phenotyp- 
icChange is described in detail in Figure 4 and is discussed 
below). The literatureReferences attribute lists one or more 
publications describing each particular study. When the 
cell type in which the identification has been carried out 
is known, it is represented by the cellType attribute, which 
is encoded by the Cell Ontology [41]. When available, the 
attributes interfaceDiscovered and residuesFound indicate 
the parts of the protomers that have been found to interact 
in the Oligomer in the given study (see below). A proto­
typical example of the attribute interfaceDiscovered is 
offered by rhodopsin dimers [42]. Specifically, based on
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the AFM-based atomic model of rhodopsin dimers (Meth- 
odType = AFM, literatureReferences = [43]) the intradimeric 
contacts have been described as involving TM4 and TM5
[42] (interfaceDiscovered = {TM4, TM5}, where TM4 and 
TM5 are stored as instances of SecondaryStructureElement 
in the composedOf attribute of InteractionDomain, 
described below). O f note, a recent crystal structure of a 
photoactivated deprotonated intermediate of bovine rho­
dopsin has shown TM1 as an alternative dimerization 
interface [44]. The IdentificationStudy concept also 
includes a measurements attribute, which records how var­
ious experimental measurements obtained in the study 
are affected by treatment with ligands (see LigandEffec- 
tOnMeasurement, below). This attribute stores the effect 
of ligands on the experimental measurements performed 
in the study (see below, and Figure 4).
3.2 InteractionDomain
The InteractionDomain concept groups functionally or 
topologically related sets of residues that may or may not 
be adjacent in sequence. Other InteractionDomain con­
cept attributes include domainName (e.g., extracellular, 
intracellular, transmembrane), and the protomer attribute 
that indicates what protein the defined interaction 
domain belongs to. If the domain can be mapped to 
defined secondary structure elements of the protomer, 
this information is stored in the composedOf attribute. For 
example, an InteractionDomain with domainName = 
extracellular would include four SecondaryStructureEle- 
ments in the composedOf attribute, where the elementName 
would be N-term, EC1, EC2 and EC3, respectively. In the 
above example of rhodopsin dimers, there would be one 
InteractionDomain instance defined: with protomer = rho­
dopsin, domainName = TM4_5, and two instances of Sec­
ondaryStructureElement in the composedOf attribute, one 
with elementName = TM4, the other with elementName = 
TM5. The interactingResidues attribute is used in cases 
where it is known which residues in a domain interact at 
the interface (see below).
3.3 Residue
Information on the residues that are involved in the inter­
action at the interface is limited. To accommodate cases 
where this information is known we have included a Res­
idue concept. The Residue concept represents a single res­
idue. Similarly to the InteractionDomain concept, the 
protomer attribute of the Residue concept indicates to 
which protein the residue belongs, since a residue at the 
dimerization interface may belong to any of the protom ­
ers of the Oligomer. The protomer attribute for the various 
residues of a particular interface would be the same pro­
tein for homodimers, and either A or B for heterodimers. 
The position attribute is the absolute position of the resi­
due in the protomer sequence, residueCode is the one letter 
code for the residue, and tmIndex and residueIndex support
the generic numbering system described in [21,22]. For 
instance, in the case of the dopamine D2 receptor, 
cysteine cross-linking studies have identified specific resi­
dues of TM4 at the interface of dopamine D2 receptor 
homodimers. One of these residues is Cys168458 at the 
extracellular end of TM4. Thus, this information can be 
represented as follows in  the ontology: MethodType = 
Cross-linking, interfaceDiscovered = InteractionDo­
main: domainName = TM4, residuesFound = Cys168458, lit­
eratureReferences [45]). In the Residue concept, residue 
Cys168458 would be represented by protomer = dopamine 
D2, residueCode = C, position = 168, tmIndex = 4 and resi- 
dueIndex = 58.
3.4 MethodType
The MethodType concept has three attributes: method- 
Nam e, explanation and isComputational. The attribute meth- 
odName stores the abbreviation or common name of the 
method; the explanation attribute stores the description of 
that method. The attribute isComputational refers to 
whether the method is computational or experimental. 
The concept MethodType is further subdivided into Crea- 
tionMethod and IdentificationMethod (see Figure 3). 
IdentificationMethod stores any method used to identify 
the existence of an oligomer. CreationMethod stores any 
method that can guide the prediction of the oligomeric 
interface leading to a 3D model of the complex. For exam­
ple, a subclass of the IdentificationMethod concept 
describing the experimental m ethod coimmunoprecipita- 
tion would have methodName = COIP, explanation = coim- 
munoprecipitation and isComputational = FALSE. Another 
subclass to be considered may be FRET (also shown as an 
example in Figure 3). The CreationMethod concept 
includes, but is not limited to, experimental or computa­
tional techniques such as AFM, and CMA (see Figure 3). 
Methods such as cross-linking can be considered to be 
examples of both CreationMethod and Identification- 
Method.
3.5 LigandEffectOnMeasurement
Treating an oligomer with a ligand can change the inten­
sity of a measured signal (i.e., am ount of co-immunopre- 
cipitation, BRET signal, etc.). The concept 
LigandEffectOnMeasurement encodes this information 
for each ligand tested in a study (the type of measurement 
tested is specified in the IdentificationStudy instance that 
refers to this measurement). This concept includes three 
attributes: ligandUnderTest, measuredEffect and phenotypic- 
Change. The attribute ligandUnderTest stores the ligand 
used for treatment. The attribute measuredEffect stores how 
the measured signal changes upon ligand treatment 
(INCREASED, DECREASED, UNCHANGED, 
NOT_TESTED). If there was also a phenotypic change 
recorded with this ligand (relative to any of the compo­
nent protomers), this change would be stored in the phe-
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notypicChange attribute (see Section 6 for details). For 
example, four instances of LigandEffectOnMeasurement 
would be used to encode the BRET measurements made 
on cholecystokinin (CCK) type A receptor in an experi­
m ent carried out by Cheng et al. [46], where the carboxyl- 
terminal was tagged with Renilla luciferase or yellow flu­
orescent protein. In the presence of the two agonist lig­
ands CCK and gastrin-4 (= ligandUnderTest), the signal 
was observed to be reduced and the measuredEffect in both 
cases would be stored as DECREASED. In the presence of 
the partial agonist [CCK-26-32]-0-phenylethyl ester 
(OPE), the effect was also reduced (although to a lesser 
degree). This change would also be stored as measuredEf­
fect = DECREASED. When the antagonist [(D-Trp30)CCK- 
26-32]-O-phenylethyl ester (D-Trp-OPE) was used, the 
measuredEffect was UNCHANGED [46].
While a num ber of published articles have interpreted lig­
and effects on such measurements as evidence of changes 
in oligomerization state, our ontology puts the emphasis 
on the storage of experimental results and leaves the inter­
pretation of these results to the end-users of the informa­
tion.
4. Molecular structures and computational simulations 
Figure 3 presents the concepts that encode structural 
information and the results of simulation studies on 
GPCR oligomers. The structuralModels attribute of Oli­
gomer identifies any type of 3D structural information 
that relates to the Oligomer.
4.1 MolecularStructure
Molecular models or experimentally determined struc­
tures are encoded as instances of the concept Molecu- 
larStructure. The creation attribute of MolecularStructure 
describes the protocol followed to create the model, or 
indicates the experimental technique used to determine 
the structure. Only instances of the CreationMethod sub­
class of the MethodType concept are used to store infor­
mation about the methods used to determine a 3D 
structure. Examples of instances of the concept Molecu- 
larStructure are: a) the different crystal structures of the 
extracellular ligand-binding region of the homodimeric 
metabotropic glutamate receptor subtype 1 [47,48], b) the 
semi-empirical model of mouse rhodopsin oligomers 
deduced from AFM studies in native disk membranes
[43], and c) correlated mutation-based models such as the 
ones described for opioid receptor [49] or dopamine D2 
receptor [45] homodimers. There are two attributes to 
store references regarding the MolecularStructure. The 
attribute databaseReferences includes references to other 
databases with information about this structure while the 
literatureReferences stores any articles from the scientific 
literature about the structure. Although the two types of
references are represented in the same way in our ontol­
ogy, it is useful to distinguish the two types.
The predictions attribute stores structural or functional 
hypotheses that were derived from the analysis of the 
molecular structure. A given molecular structure can be 
used in multiple computational analyses, and these are 
stored in the analyses attribute. Similarly, several molecu­
lar simulation studies (e.g., molecular dynamics, normal 
mode analysis, etc.) can be performed on the same struc­
ture, and are also listed under the attribute analyses. 
Optionally, an images attribute of MolecularStructure (not 
included in the ontology) could offer a way to present 
users with illustrations of structural information.
4.2 Analysis
The Analysis concept stores information about all compu­
tational procedures that have been used to create and to 
analyze the 3D molecular structure of the oligomer. It 
includes three attributes: technique, programNamesUsed 
and literatureReferences. The attribute technique stores the 
name of the technique used in the analysis, and program­
NamesUsed lists the names of the computational packages 
that were used in the analysis. Rather than detailing all the 
minutiae of the analysis in the ontology, the interested 
user will be directed to the journal articles (listed in litera- 
tureReferences) that describe the analysis.
5. Mechanism of activation
The concept MechanismOfActivation in Figure 4 allows 
the storage of information about mechanistic hypotheses 
of oligomeric activation.
Current models of ligand binding and signal transduction 
by GPCR dimers can be described as symmetric or asym­
metric depending on whether or no t both protomers of 
the dimer undergo similar or different conformational 
changes upon activation. The ligand that is responsible for 
the activation mechanism being described in a given 
instance of MechanismOfActivation is stored in the acti- 
vatingLigands attribute. The list of protomers that undergo 
a conformational change leading to activation of the oli­
gomer is stored in the activatedProtomers attribute. The 
attribute undergoesInterfaceRearrangement indicates 
whether or no t this conformational change is known to 
involve domains or residues at the oligomerization inter­
face. A summary of the specific types of structural change 
within a protomeric unit will be contained in the attribute 
descriptionOfChange (e.g., "TM6 moves away from TM3"). 
Details will be found in the associated publication, which 
information is stored through the attribute literatureRefer- 
ences. The attribute deducedFromStudies provides informa­
tion about the computational/experimental studies that 
suggested the specific mechanistic hypothesis of activa­
tion.
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The attribute bindingSiteOccupancy indicates how many 
ligand binding sites are occupied in a given GPCR oli­
gomer. The attribute isAsymmetric allows discrimination 
between hypotheses of symmetric or asymmetric activa­
tion for a given GPCR oligomer. The particular case of 
asymmetric activation in which one protomer of a GPCR 
dimer is not capable of G-protein coupling, whereas the 
other protomer can bind the G-protein but not the ligand 
will be denoted by the attribute isTransactivated set to 
TRUE. On the other hand, if the ligand-bound protomer 
that undergoes a conformational change is also the one 
that activates the G-protein, the mechanism of activation 
is referred to as cis-activation, and the attribute isCisacti- 
vated will be set to TRUE. Both, cis- and trans-activation 
attributes are not mutually exclusive and could both be 
TRUE. Finally, the stoichiometry of the signaling complex, 
i.e., how many GPCRs and G-proteins form a functional 
GPCR oligomer, is expressed by use of the attributes num- 
berGPCRs and numberGProteins.
The most unambiguous example of trans-activation has 
been described for the GABAB1-GABAB2 heterodimer, 
where the ligand-bound subunit (GABAB1) does not 
appear to couple to the G-protein, but the other subunit 
(GABAB2) within the hetero-dimer can bind the G-pro- 
tein, but not the ligand [50]. Thus, for the GABAB1- 
GABAB2 heterodimer the attribute isTransactivated would 
be set to TRUE. On the other hand, studies of the hista­
mine H1 receptor and a1B-adrenoreceptor homodimers
[51] provide mechanistic hypotheses of cis-activation (i.e., 
the protomer that binds the ligand and undergoes the 
conformational change is the same protomer that acti­
vates the G-protein). Hence they will be identified by set­
ting isCisactivated = TRUE. Analysis of GABAb chimeric 
subunits seems to suggest that in other homodimeric 
classes of GPCRs, in which both "subunits" are capable of 
binding ligand and signaling to G-protein, both cis- and 
trans-activation may take place [50]. In fact, in the case of 
the luteinizing horm one receptor dimer the binding of 
horm one seems to activate adenylyl cyclase through the 
same receptor TM bundle (cis-activation), as well as trans- 
activate through the TM bundle of an adjacent receptor
[52]. Therefore in this example isCisactivated = TRUE and 
isTransactivated = TRUE.
A more generic example of asymmetric activation (isAsym- 
metric = TRUE) is represented by the metabotropic gluta­
mate (mGlu) homodimers [53,54]. Using a new class of 
synthetic allosteric modulators (information about them 
would be contained in the LigandEffectOnMeasurement 
concept, see above), recent studies have suggested that 
only one heptahelical domain of the mGlu homodimer 
can undergo activation. In this case of asymmetric activa­
tion, it has also been demonstrated that the binding pock­
ets of both ectodomains of the mGlu homodimer must be
occupied for full activation of the system (bindingSiteOc­
cupancy = 2) [55].
An elegant experimental study of the leukotriene B4 
receptor (BLT1) suggests that a functional GPCR complex 
is composed of one heterotrimeric G-protein and one 
GPCR dimer [56] (numberGPCR = 2; numberGProtein = 1). 
Indeed, one protomer only is active in such dimers in the 
presence of the G-protein, and this is sufficient for full G- 
protein activation (see Damian et al. [57]). Stoichiometry 
may become even more complicated in the case of GPCR 
oligomers, as recently suggested by Palczewski's lab based 
on inferences from AFM studies [58]. As per the specific 
conformational changes that BLT1 undergoes, experimen­
tal evidence suggests a rearrangement of TM6 [56]. This 
information will be stored under descriptionOfChange = 
"TM6 rearrangement".
Examples of undergoeslnterfaceRearrangement = TRUE have 
been reported for the mGluR1 and dopamine D2 recep­
tors. Specifically, crystallographic structures of glutamate- 
bound and unbound forms of mGluR1 [47,48] provide 
evidence for the rearrangement of the extracellular 
dimeric conformations, which may subsequently induce a 
conformational change in the cytoplasmic regions [59]. 
Finally, cross-linking studies (= deducedFromStudies) of 
dopamine D2 receptor in the presence of agonists and 
inverse agonists also suggest a conformational rearrange­
m ent of the TM4 homodimeric interface upon activation 
[60].
6. Phenotypic changes
The phenotype attribute of IdentificationStudy encodes the 
change of phenotype associated with oligomerization 
(the association observed in the study described by Iden- 
tificationStudy). Our ontology only encodes changes in 
phenotype that are observed in the presence of different 
combinations of GPCRs with their associated ligands [2]. 
A change occurs if the phenotype of the Oligomer is sig­
nificantly different from the phenotype of either one of 
the protomers (or the homodimers of those protomers) 
that participate in the Oligomer. The comparedWith 
attribute stores the protomer relative to which the pheno­
typic changes stored in PhenotypicChange are being com­
pared. Figure 4 shows that the GPCR oligomerization 
ontology distinguishes between three types of phenotypic 
changes: internalization, ligand binding, and signaling 
changes. The PhenotypicChange concept does not include 
a literatureReferences attribute since they are already listed 
in the IdentificationStudy concept.
6.1 Internalization
The ontology tracks reported changes to internalization of 
the oligomer with respect to internalization of the m ono­
mer using four attributes: ligandInvolved, readoutProtomer,
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boundProtomer and isInternalized. Internalization, traffick­
ing from the cell membrane, is usually observed upon lig­
and stimulation, and different effects are often observed 
with different ligands.
Each tested ligand (attribute ligandInvolved) is associated 
with its bound protomer (attribute boundProtomer), and to 
the internalization effect observed (isInternalized) on the 
protomer being studied (readoutProtomer).
An example of an instance of the Internalization concept 
is provided by confocal microscopy studies carried out on 
co-expressed sst2A somatostatin receptor and ^-opioid 
receptors. Treatment with a sst2A-specific ligand, L- 
779,976, induces the internalization of both the sst2A and 
^-opioid receptors, bu t treatment with a ^-opioid receptor 
specific ligand, [D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin 
(DAMGO), only induced the internalization of ^-opioid, 
not of sst2A. These three results would be stored as 1) 
boundProtomer = sst2A, ligandInvolved = L779,976, readout­
Protomer = {sst2A, ^-opioid} and isInternalized = TRUE; 2) 
boundProtomer = sst2A, ligandInvolved = DAMGO, readout- 
Protomer = sst2A and isInternalized = FALSE; 3) boundPro­
tomer = ^-opioid, ligandInvolved = DAMGO, 
readoutProtomer = ^-opioid and isInternalized = TRUE [61].
6.2 Ligand binding
The concept LigandBinding encodes differences in the 
binding of a given ligand to the Oligomer with respect to 
the protomer. This concept is defined by the following 
attributes: a) the ligand tested in the pharmacological 
assay (ligandUnderTest), b) the property of ligand action, 
indicating whether the ligand is an agonist, partial ago­
nist, antagonist, neutral antagonist or inverse agonist (lig­
andProperty), c) the protomer (or protomers) that the 
ligand is observed to bind (protomersBound), d) the meas­
ured change in ligand affinity to the oligomer compared 
to the protomer (affinityChange), and e) the presence of 
demonstrated ligand binding crosstalk (bindingXTalk) -  
see section 6.4. The helper concept MeasuredVariation 
records if the affinity was: INCREASED, DECREASED, 
NOT CHANGED, or NOT_TESTED.
Results of |i- and 8-opioid receptor co-expression can be 
used as an example of the type of information that 
attributes of the LigandBinding concept will contain. 
Experimental data indicate that the |i-8 opioid oligomeric 
complex exhibits a 10-fold lower affinity for both the |i- 
selective agonist DAMGO and the 8-selective agonist [D- 
Pen2, D-Pen5]enkephalin (DPDPE) (comparedWith = |i- 
opioid receptor and 8-opioid receptor, respectively) [62]. 
The information can be represented by two instances of 
LigandBinding as follows: 1) ligandUnderTest = DAMGO, 
protomersBound = {^-opioid receptor}, affinityChange = 
DECREASED; 2) ligandUnderTest = DPDPE, protomers-
Bound = {8-opioid receptor}, affinityChange = 
DECREASED. On the other hand, endogenous opioid 
peptides such as endomorphin-1 (= ligandUnderTest; pro­
tomersBound = {^-opioid}) and Leu-enkephalin (protomer­
sBound = {8-opioid, ^-opioid}) have enhanced affinity 
(affinityChange = INCREASED) for the heteromeric opioid 
receptor complex (comparedWith = ^-opioid receptor). 
[62].
6.3 Signaling
GPCRs mostly signal through heterotrimeric G proteins 
although increasing evidence suggests that GPCRs may 
also function in a G-protein-independent manner. In this 
section we only refer to classical G protein-dependent sig­
naling pathways, although the ontology can incorporate 
information about G protein-independent signaling path­
ways as well.
GPCR oligomers can signal through different pathways 
than a GPCR monomer. The Signaling concept makes it 
possible to encode such differences in downstream signal 
transduction. Encoding of this concept assumes that a 
molecule (in attribute molecule) that belongs to a pathway 
(in attribute pathway) downstream of the receptor has 
been tested (the type of assay can be described in the 
attribute measurementType). The attribute changeInMeas- 
urement records either how the output of the assay differs 
from the m onom er to the oligomer or the effect that dif­
ferent cross-talk ligands have on specific ligand-mediated 
signaling processes (see signalingXtalk attribute below). 
For instance, if the levels of cAMP are tested, and the cor­
responding assay reports that cAMP levels are higher for 
the oligomer than for the monomer, then changeInMeas- 
urement will have the value INCREASED. The attribute 
activatingLigand records which ligand was used to activate 
the receptor. The attribute isDesensitized is used to report 
the loss of responsiveness of the protomer to the continu­
ing or increasing dose of activatingLigand. The attribute 
isPhosphorylated contains information about whether the 
GPCR receptor is phosphorylated or not. Further, the 
attribute signalingXTalk indicates if the signal transduction 
change corresponds to crosstalk between signaling path­
ways mediated by the protomers of the Oligomer (see sec­
tion 6.4). Finally, changes in G-protein specificity are 
accounted by the attribute gProteinType. This attribute is 
part of the Signaling concept rather than Oligomer as the 
G-protein specificity is dependent on the ligand.
For example, in cells co-expressing sst2A and ^-opioid, 
addition of L779,976 to the system is able to promote 
phosphorylation and desensitization of both receptors, 
compared with the ^-opioid receptors expressed alone. 
This is stored as comparedWith = ^-opioid, activatingLigand 
= L779,976, readoutProtomer = {sst2A, ^-opioid}, isPhos- 
phorylated = TRUE, isDesensitized = TRUE; 2) [61].
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An example of possible changes in G-protein specificity 
can be illustrated by the effect of agonist stimulation on 
co-expressed dopamine D1 and D2 dopamine receptors. 
Stimulation results in an increase of intracellular calcium 
levels via a signaling pathway not activated by either 
receptor alone or when either one of the co-expressed 
receptors was activated by a selective agonist. Further­
more, calcium signaling by D1-D2 dopamine receptor co­
activation was abolished following treatment with a phos­
pholipase C inhibitor bu t not with pertussis toxin or 
inhibitors of protein kinase A or protein kinase C, indicat­
ing coupling to the Gaq pathway. This information would 
be stored as molecule = Ca2+, pathway = phospholipase C 
dependent pathway, readoutProtomer = {dopamine D1, 
dopamine D2}, gProteinType = G aq [63].
The use of some of the other attributes in Signaling can be 
demonstrated using the experiments by Breit et al. on het­
erologous systems co-expressing sensory neuron-specific 
receptors subtype 4 (SNSR-4) and 8-opioid receptors [64]. 
When these receptors are co-expressed in HEK-293 cells, 
each receptor acts as an independent unit. In the heterol­
ogous system, the SNSR4 selective bovine adrenal 
medulla peptide BAM22 produces similar amounts of 
phospholipase C activation as it does in cells expressing 
only SNSR4. This is stored as: comparedWith = SNSR4, mol­
ecule = phosphoinositol, pathway = phospholipase C, 
measurementType = induced accumulation of total phos- 
phoinositols, activatingLigand = BAM22, gProteinType = 
Gaq, changeInMeasurement = UNCHANGED.
6.4 CrossTalk
The attributes signalingXTalk and bindingXTalk are used to 
describe changes in the affinity or signaling of the ligandA 
(i.e., the ligand bound to protomer A of the oligomer, 
which should be the same as the value of the attribute lig- 
andUnderTest of the referring instance of LigandBinding, 
or ligand in Signaling) in the presence of another ligand 
(i.e., a ligand bound to protomer B of the oligomer). The 
concept CrossTalk includes attributes that account for the 
specific ligands (ligandA and ligandB) and protomers (pro­
tomerA and protomerB) involved in changes in affinity 
(when referred to LigandBinding or signaling when talk­
ing of signalingXtalk) due to crosstalk (changeInPro- 
tomerA).
An example of bindingXTalk (sometimes called positive/ 
negative cooperativity) can be seen in the treatment of 
cells or native membranes containing both ^-opioid (= 
protomerA) and 8-opioid (= protomerB) receptors [65,66] 
with low doses of a selective 8-opioid ligand such as 
TIPPT (H-Tyr-TicT [ CH2NH ] Phe-Phe-OH) (=ligandB) 
produces a two-fold increase in binding affinity (changeIn- 
ProtomerA = INCREASED) of the ^-opioid agonist 
DAMGO (= ligandA). Figure 5 illustrates pictorially this
example together with three other experiments carried out 
in the same cell system.
Similarly, for signalingXTalk, in vivo analgesia studies 
have shown that pretreatment of mice with the 8-selective 
agonist naltrindole NTI lowers the antinociceptive 
potency values (ED50) of compounds such as MDAN-19 
and MDAN-16 to either 8 -  or ^-opioid receptors, bu t has 
no effect on MDAN-21 potency [67]. This MDAN (|i-ago- 
nist-8-antagonist) series of bivalent ligands has been 
designed by combining pharmacophores from oxymor- 
phone (^-opioid receptor agonist) and NTI (8-opioid 
receptor antagonist). Thus, this information will be 
entered as follows: ligandA = MDAN21, protomerA = |i- 
receptor, ligand B = NTI, protomerB = 8-receptor, changeIn- 
ProtomerA = UNCHANGED, or MDAN16, protomerA = |i- 
receptor, ligand B = NTI, protomerB = 8-receptor, changeIn- 
ProtomerA = DECREASED.
7. Physiological relevance
A growing body of evidence refers to the existence of 
GPCR oligomers in native tissue. This information is 
extremely im portant as it relates to the physiological rele­
vance of the GPCR oligomer under study. Whether or not 
all protomers of an oligomer are identified in the same 
cell or within the same subcellular compartments (colocal- 
izationEnvironment) will be indicated by the isColocalized 
attribute. Specific functional properties for the GPCR oli­
gomers identified in native tissue (e.g., positive or nega­
tive allosteric interaction between the two binding sites of 
a GPCR dimer, information about a ligand specific to the 
dimer, activation of a specific signaling pathway, or spe­
cific internalization or desensitization properties) will be 
stored via the inVivoPhenotypicChange attribute. As the use 
of knock out animals or RNAi technology may also pro­
vide key information on the existence of GPCR oligomers 
in vivo, this information will be stored as well using the 
geneKnockoutResponse attribute.
The case of GABAB receptors is used here to provide an 
example of the physiological information that can be 
stored using the attributes described above. For instance, 
to indicate that subunits GABAB1 and GABAB2 are co-local­
ized in the brain [34], we will use the attributes isColocal- 
ized = TRUE and colocalizationEnvironment = brain. The 
deletion of either GABAB1 [68] or GABAB2 [69] in mice 
leads to similar phenotypes with no detectable GABAB 
responses (=geneKnockoutResponse).
Discussion
As data about GPCR oligomerization accumulate in the 
scientific literature, it becomes appropriate to create an 
electronic repository to facilitate the browsing, searching 
and integration of relevant data. However, the construc­
tion of such a resource is no t trivial because the resource
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should offer information about many various aspects of 
GPCR oligomerization and how these aspects interrelate. 
To enable the construction of a GPCR oligomerization 
information system that is as complete and responsive to 
the needs of the GPCR community as possible, we have 
gathered the requirements of such a system from experi­
mental and computational experts in the GPCR field. 
Based on an interdisciplinary dialog, we have created an 
ontology that formalizes information concepts and con­
cept relationships required to store the different aspects of 
GPCR oligomerization in an electronic repository. These 
concepts are formally defined in the OWL language, a 
W3C standard for ontology exchange [70] recognized by 
the Open Biomedical Ontologies consortium (OBO)
[71]. Since XML-based exchange formats can be generated 
from an ontology (e.g., as is done in the BioPax project
[72]), the GPCR Oligomerization ontology can also sup­
port the exchange of data among other GPCR oligomeri­
zation-aware systems.
Many ontologies proposed under the OBO consortium 
can be reused in a variety of applications (e.g., the Cell 
Ontology provides an ontology of cell types useful for a 
variety of bioinformatics resources [41] and is re-used in 
the ontology described here, as part of the Identification- 
Study concept). However, many successful ontologies 
have a more restricted focus, such as the EcoCyc ontology. 
The EcoCyc ontology offers a consensual view of how 
information about the E. coli metabolic pathways could 
be stored electronically [73,74]. The GPCR Oligomeriza­
tion ontology is similarly necessarily restricted in its focus, 
having been designed to make possible the development 
of a GPCR oligomerization information system.
Although reusability of the GPCR Oligomerization ontol­
ogy is likely to be limited, we expect that ideas expressed 
in this ontology, for instance about how phenotypic 
changes are represented (see below and Figure 4), may be 
useful in other fields. Although there are other large-scale 
projects underway to define phenotype ontologies (i.e., 
the mammalian phenotype ontology (MPO) [75]), the 
phenotypic representation required by the GPCR oli­
gomerization system falls outside of the utility of the 
MPO ontology. Specifically, (1) the current focus of MPO 
is on phenotype observed at the organ, organism and cell 
levels. These phenotypes do not match the pharmacolog­
ical and signaling phenotypes most often considered in 
the GPCR field; (2) MPO models phenotypes, while 
reports available in the literature for GPCR oligomers gen­
erally characterize phenotypic changes (e.g., the affinity of 
ligand X is increased in the oligomer compared to that in 
the protomer alone); (3) the tree structure of the MPO 
assumes that each phenotype is represented as a distinct 
concept of the ontology. Categorizing each distinct phe­
notype with a different concept of the ontology in this
way does no t support computational comparisons of phe­
notypic changes required by a GPCR oligomerization 
information system. For example, obtaining the list of lig­
ands whose binding to the Oligomer is increased when 
compared to binding of the same ligand to the protomer 
is possible with our ontology, but not with the relations 
offered by MPO.
In contrast to the MPO hierarchy of phenotypes, the solu­
tion that we retained for the GPCR Oligomerization 
ontology models phenotypic changes as concepts which 
are endowed with attributes that support explicit compar­
ison and aggregation of phenotypic changes (a pheno­
typic change that follows this approach is illustrated in 
Figure 5). In this respect, the choices made in the GPCR 
Oligomerization ontology are driven by the types of com­
putation that we expect an information system will per­
form with GPCR oligomerization information. Since 
protein oligomerization and its impact on downstream 
signaling pathways is a regulation and signaling paradigm 
that occurs in a variety of non-GPCR systems, we antici­
pate that our representation of phenotypic changes will be 
reusable in other fields, e.g., protein kinases. The phos­
phorylation of a protein by a protein kinase may change 
its enzymatic activity, cellular location or association with 
other proteins. The GPCR Oligomerization ontology 
models such changes at an intermediate level of detail 
which omits mechanistic and precise stoichiometric 
details, yet captures the information most useful to scien­
tists who study these regulation mechanisms experimen­
tally.
Although the ontology presented here will continue to 
develop as studies of GPCR oligomerization progress, the 
version of the GPCR Oligomerization ontology presented 
in this manuscript is expected to facilitate the develop­
m ent of future GPCR oligomerization information sys­
tems. The information that is entered into systems based 
on this ontology can be manually extracted from the liter­
ature by expert curators. Because of the possibility of sev­
eral different interpretations of the primary data presented 
in an article, our ontology focuses on primary experimen­
tal data that are objective and not subject to interpreta­
tion. In addition to primary data, reported oligomeric 
complexes of GPCRs that satisfy one or more of the rules 
recently specified by NC-IUPHAR will be properly high­
lighted.
It is worth underscoring that attributes of inference have 
been avoided in the construction of this ontology, in 
order to offer as objective and neutral information as pos­
sible. The user will find always a referenced article or arti­
cles for further reading and discussion on the topic of 
interest. Our m ain goal has been to reflect the information 
as close to the data as possible so the user can compare
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related studies and make his or her own inferences or 
judgments on the conclusions provided by the study or 
studies available. For example, in Angers et al., isoprotere­
nol was suggested to induce homodimerization of the P2- 
adrenergic receptor based on inferences from BRET results 
[76]. However, further studies with a modified and newer 
version of BRET reported that stimulation with the same 
agonist did not promote consistent change in the BRET 
saturation curves. Thus, the authors concluded that the 
dimers form constitutively, and that receptor activation 
does no t affect their oligomerization state [77]. In this 
ontology both examples will be collected as part of iden­
tification studies related to P2-adrenergic receptor 
homodimers. However, only the increased or unchanged 
BRET signal in the presence of that agonist will be 
reported, with omission of any inference about oligomer 
formation.
The construction of the GPCR Oligomerization ontology 
may also lend itself to the possibility of automatically 
extracting information that can be directly added to a 
database based on that ontology. Curated databases (such 
as the one under development in our laboratories) require 
curators to read and interpret a manuscript to extract 
information that will be added to the database. A more 
collaborative strategy could be proposed where structured 
information would be embedded in articles in such a way 
that the extraction of information can be automated and 
will no t require hum an interpretation. The advantage of 
this strategy is that the structured information would be 
reviewed at the same time as the manuscript and that it 
would solve the problem of information extraction from 
the literature. The ontology described in this manuscript 
would support such a strategy because it is possible to 
automatically generate a structured language from an 
ontology that could be used to encode information for 
embedding in a manuscript. We note that while this strat­
egy is possible, there are still a num ber of sociological bar­
riers to its widespread use. In the meantime, the GPCR- 
OKB ontology presented here will be useful to database 
designers and curators who need to manage information 
about GPCR oligomerization.
Conclusion
We have presented the requirements and ontology of an 
information system designed to manage the elements of 
information necessary to describe the phenom ena of both 
homo- and hetero-oligomerization of GPCRs in a data- 
driven manner. The elements of information supported 
by the GPCR Oligomerization ontology include: i) links 
to other databases with information about GPCR protom ­
ers, ii) information about the experimental details of 
methods used to study GPCR oligomers, iii) experimental 
evidence for and computational predictions of the specific 
residues at oligomeric interfaces, iv) structural models of
oligomers deduced from experiments or computer simu­
lation studies; v) information about potential mecha­
nisms of activation of GPCR oligomers; vi) information 
about functional roles of GPCR oligomers and the various 
phenotypical changes that occur compared to the individ­
ual subunits; vii) novel compounds that are proposed to 
selectively target GPCR oligomers; viii) the possible phys­
iological relevance of GPCR oligomers.
The requirements and ontology described in this m anu­
script will facilitate the development of future GPCR oli­
gomerization information systems that will integrate data 
generated by experimental and computational studies of 
GPCR oligomerization. The one under current develop­
m ent in our laboratories (GPCR-OKB) will be continually 
curated and maintained.
Availability and requirem ents
The ontology for g Pc R-OKB is available at http:// 
www .gpcr-okb.org.
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